ABSTRACT
OBJECTIVES: The aim of this retrospective study was to evaluate the efficacy of bypass in patients with endstage renal disease (ESRD) and to determine predictive factors and precise bypass indications. METHOD: Forty one patients with ESRD underwent 50 bypass, 6 limbs were stage II and 44 stage III or IV according to Leriche and Fontaine classification. Revascularisations procedures were 47 infrainguinal bypass and 3 miscellaneous. Median follow up was 17,0+/-15,7 months. RESULTS: Perioperative mortality rate was 12% (n = 6). Morbidity was as follow : 1 perioperative major imputation and 8 secondary ones. There were 26 secondary death (12 from cardiac events), cumulative survival rate declined to 42,9+/-7,7% and limb salvage rate to 77,2+/-7,5% at 2 years. Primary and secondary potency rates were 53,5+/-10,4% and 70,6+/-10%. Quality of life was good in 28% of revascularised patients. Among risk factors, myocardial events showed a statistical significance in predicting survival, good runoff and bypass occlusion showed a statistical significance in predicting limb salvage. CONCLUSION: Revascularisation can be performed in ESRD patients. However to improve the results full evaluation of myocardial risks, skin lesions and infection of the feet, available autologous vein and nutritional status may be needed in those patients.
Subject(s)
Kidney Failure, Chronic/surgery , Vascular Surgical Procedures , Adult , Aged , Aged, 80 and over , Female , Humans , Inguinal Canal/blood supply , Inguinal Canal/surgery , Kidney/blood supply , Kidney Failure, Chronic/complications , Male , Middle Aged , Morbidity , Prognosis , Retrospective Studies , Treatment OutcomeSubject(s)
Carcinoma, Signet Ring Cell/secondary , Deoxycytidine/analogs & derivatives , Muscle Neoplasms/secondary , Muscle, Skeletal/pathology , Urinary Bladder Neoplasms/pathology , Adrenal Cortex Hormones/administration & dosage , Aged , Antimetabolites, Antineoplastic/administration & dosage , Antineoplastic Combined Chemotherapy Protocols/therapeutic use , Buttocks , Carcinoma, Signet Ring Cell/diagnosis , Carcinoma, Signet Ring Cell/drug therapy , Deoxycytidine/administration & dosage , Humans , Hypertrophy/etiology , Male , Muscle Neoplasms/diagnosis , Muscle Neoplasms/drug therapy , Muscular Diseases/etiology , Neoplasm Recurrence, Local , Thigh , Treatment Outcome , GemcitabineABSTRACT
OBJECTIVES: To determine the outcome and the place of transluminal angioplasty (ATL) in the treatment of severe limb ischaemia. MATERIALS AND METHODS: Seventy two legs at stage III and IV of Fontaine's classification have been exclusively treated by endoluminal procedures. The success was valued both on the haemodynamic post-operative improvement of the run-off flow and on the clinical statut leading to the conservation at mid-term of a functional limb. Patency and survival rate had been valued by actuarial method. RESULTS: Seventy percent of the limbs were haemodynamically improved. For the global population, a 48% clinical success rate was obtained at 6 months but 30.5% of limbs were loss. Primary patency rate was respectively 79, 71 and 68% at 6, 12 and 24 month. The quality of the run-off arteries has been the most influential factor. CONCLUSION: Endoluminal treatment of chronic limb ischaemia had lead to a clinical improvement in 48% of cases. Multi-stages and distal atherosclerotic disease of this patients limits ATL indications which results depend of run-off quality.
